Table 3.

Incidence of selected vaccine-related adverse events by a history of herpes zoster

Adverse events	Healthy adults		Patients with underlying illnesses		Patients with malignancy		Patients with diabetes mellitus		Patients with autoimmune diseases		Patients with chronic renal diseases
	No. of events	No. of subjects (%) (95% CI)	No. of events	No. of subjects (%) (95% CI)	No. of events	No. of subjects (%) (95% CI)	No. of events	No. of subjects (%) (95% CI)	No. of events	No. of subjects (%) (95% CI)	No. of events	No. of subjects (%) (95% CI)
Subjects with HZ history	N = 155		N = 49		N = 11		N = 28		N = 1		N = 9
Vaccine-related AEs	198	87 (56%) (48–64%)*	54	23 (47%) (33–62%)	8	4 (36%) (11–69%)	30	13 (46%) (28–66%)	6	1 (100%)	10	5 (56%) (21–86%)
Injection-site AEs	189	82 (53%) (45–61%)*	54	23 (47%) (33–62%)	8	4 (36%) (11–69%)	30	13 (46%) (28–66%)	6	1 (100%)	10	5 (56%) (21–86%)
Systemic AEs	9	8 (5%) (2–10%)	0	0 (0%)	0	0 (0%)	0	0 (0%)	0	0 (0%)	0	0 (0%)
Subjects without HZ history	N = 1045		N = 251		N = 38		N = 152		N = 9		N = 52
Vaccine-related AEs	1164	422 (40%) (37–43%)	274	102 (41%) (35–47%)	36	16 (42%) (26–59%)	167	60 (39%) (32–48%)	8	4 (44%) (14–79%)	63	22 (42%) (29–57%)
Injection-site AEs	1117	409 (39%) (36–42%)	260	95 (38%) (32–44%)	33	14 (37%) (22–54%)	161	58 (38%) (30–46%)	6	3 (33%) (7–70%)	60	20 (38%) (25–53%)
Systemic AEs	47	38 (4%) (3–5%)	14	11 (4%) (2–8%)	3	2 (5%) (0.6–18%)	6	5 (3%) (1–8%)	2	1 (11%) (0.3–48%)	3	3 (6%) (1–16%)

AE Adverse event, HZ Herpes zoster

*P < 0.05, **P < 0.1 (compared with the proportion of reported subjects without HZ history within the category of subjects)